Inhibiting tumor-cell growth by novel truncated staphylococcal enterotoxin C2 mutant

Area of Science:

• Biotechnology
• Immunology
• Oncology

Background:

• Staphylococcal enterotoxin C2 (SEC2) shows potential for malignant tumor treatment.
• Clinical use of SEC2 is limited by significant side-effects, particularly emetic responses.

Purpose of the Study:

• To engineer a truncated SEC2 mutant (NSM) that retains T-cell stimulatory and anti-tumor activities.
• To eliminate the emetic properties of SEC2 while preserving therapeutic efficacy.

Main Methods:

• Truncation of the SEC2 protein to create a novel mutant (NSM).
• In vitro assessment using methyl thiazol tetrazolium (MTT) assay to evaluate T-cell proliferation and tumor cell growth inhibition.
• In vivo animal experiments to assess emetic response and anti-tumor efficacy in tumor-bearing mice.

Main Results:

• The novel truncated SEC2 mutant (NSM) demonstrated potent T-cell stimulation and inhibition of human colorectal (Cx-1) and breast (MCF-7) cancer cell growth in vitro.
• NSM exhibited comparable T-cell stimulating and anti-tumor activities to the wild-type SEC2.
• Animal studies confirmed that NSM did not induce emetic responses, even at doses 10 times higher than required for SEC2, and significantly inhibited tumor growth.

Conclusions:

• A novel truncated staphylococcal enterotoxin C2 mutant (NSM) has been successfully developed.
• NSM preserves crucial T-cell stimulatory and anti-tumor functions while lacking emetic activity.
• This engineered mutant represents a promising candidate for novel anti-cancer agents with improved safety and efficacy profiles for clinical application.